Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
09:45am, Thursday, 24'th Jul 2025
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Exagen Inc. Appoints Chas McKhann to Board of Directors
04:05pm, Thursday, 17'th Jul 2025
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Boa
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
04:05pm, Tuesday, 15'th Jul 2025
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025,
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
09:00am, Monday, 23'rd Jun 2025
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chie
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,5
Exagen Inc. Prices Public Offering of Common Stock
08:30am, Thursday, 08'th May 2025
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten
Exagen Inc. Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 07'th May 2025
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
04:51pm, Monday, 05'th May 2025
Exagen Inc. (NASDAQ:XGN ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black -
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
10:10am, Monday, 05'th May 2025
Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
08:00am, Monday, 05'th May 2025
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
09:00am, Monday, 28'th Apr 2025
$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) --
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
03:31am, Saturday, 26'th Apr 2025
We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
04:05pm, Monday, 21'st Apr 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before th
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
01:13pm, Tuesday, 11'th Mar 2025
Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
08:00am, Tuesday, 11'th Mar 2025
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility
